InvestSMART

Oncosil Medical Limited (ASX:OSL)

ALERT: Price-sensitive ASX Announcement for OSL
Current share price for OSL : $1.210 -0.11 (-8.33%)+
Announcement
Release
13 Jul 2026 8:39AM
Price at Release
$1.320
Full Release
download
Summary
OncoSil Medical Limited has successfully completed its manufacturing validation program, marking a key operational milestone in partnership with Cyclotek. This initiative has established a scalable Australian manufacturing capability, producing over 50 validation doses of the OncoSil™ device. The company has invested approximately $2.1 million in specialized production equipment and implemented a proprietary manufacturing process. This capital-efficient model is expected to improve gross margins and provide greater control over manufacturing capabilities and product quality, in compliance with ISO 13485, TGA, and FDA standards. Subject to regulatory approvals, commercial production is anticipated to commence in the second half of 2026.
Key Points
  • OncoSil Medical completed a significant manufacturing validation program.
  • The partnership with Cyclotek established a scalable Australian manufacturing capability.
  • The manufacturing program included the production of more than 50 validation doses.
  • The capital-efficient model is designed to improve margins and control over manufacturing.
  • OncoSil invested approximately $2.1 million in specialized equipment.
  • Manufacturing adheres to ISO 13485, TGA, and FDA standards.
  • Commercial production is expected to start in the second half of 2026, pending regulatory approval.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.